Lavoltidine (INN, USAN, BAN; code name AH-23,844), previously known as loxtidine, is a highly potent and selective H2 receptor antagonist which was under development as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.[1][2]

Adverse effects

Antacid preparations such as loxtidine by suppressing acid mediated break down of proteins, leads to an elevated risk of developing food or drug allergies. This happens due to undigested proteins then passing into the gastrointestinal tract where sensitisation occurs. It is unclear whether this risk occurs with only long-term use or with short-term use as well.[3]

See also